Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.